
BenevolentAI Ltd inks US$594m partnership with Merck KGaA
Under the licence agreement, BenevolentAI will identify and develop new compounds against three targets provided by Merck through hit identification...

Breakthrough in microtia treatment
Researchers of the Tissue Engineering and Biofabrication Laboratory of the ETH Zurich unveiled a novel approach to addressing microtia, a congenital...

Sanofi licences vaccine against bacterial sepsis
Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive E. coli...

microRNA could offer a safe target in atherosclerosis
The researcher demonstrateded that targeting of miR-206-3p with an experimental compound safely reversed the onset of atherosclerosis in a...

Microharvest GmbH launches SCP-Pilot plant in Lissabon
Prior to its planned product launch of HILIX, a feed product for aquaculture, in early 2024, single-cell protein start-up MicroHarvest GmbH has...

Evotech screens cancer candidates for Dewpoint Therapeutics
With this partnership, the Hamburg-based screening specialists have landed a really big deal Dewpint Therapeutics, the just four-year-old spin-off...

Breakthrough in COPD treatment
Sanofi's duplimab (Dupixent®) showcased notable efficacy in reducing exacerbations and enhancing lung function in its second positive Phase III...